Brief: Vaccinex Ends Q3 With Cash And Cash Equivalents Of $17.1 Million
13/11/2020 13:08
Nov 13 (Reuters) - Vaccinex Inc VCNX.O :
* VACCINEX REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND
PROVIDES CORPORATE UPDATE
* VACCINEX INC - ADDITIONAL DATA FROM SIGNAL HUNTINGTON'S
DISEASE
(HD) TRIAL SUPPORT CONTINUED DEVELOPMENT IN HD AND IN
ALZHEIMER'S DISEASE
* VACCINEX INC - ENDED QUARTER WITH CASH AND CASH
EQUIVALENTS OF
$17.1 MILLION
Source text for Eikon: ID:nGNX49fvSc
Further company coverage: VCNX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaccinex
See all newsBrief: Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Brief: Vaccinex Says On Oct 7, Got Letter From The Nasdaq Listing Staff Stating That Co Had Not Regained Compliance With The Equity Standard
Brief: VaccinexExercise Of Warrants For $6.2 Million In Gross Proceeds
Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
Brief: Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease